Ph2 Master Protocol with Mirvetuximab Soravtansine in Ovarian Cancer (FLORENZA)-GOG-3126

Phase II Clinical Trial

M25-709: A Phase 2 Open-Label Randomized Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA).

Indication: Ovarian Cancer

Trial Number: 07059845

Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations

‌

‌
‌